Morning Overview on MSN
A simple blood test measuring pTau217 can now predict Alzheimer’s progression years before memory loss or brain scan changes appear
Imagine a 62-year-old woman who aces every memory test her doctor gives her. Her brain scans look clean. She feels sharp. But ...
New research suggests a blood test may identify Alzheimer’s years before it is detectable on scans. Image credit: Sean Locke/Stocksy At present, diagnosis typically involves a combination of medical ...
The research study will include both those who have been diagnosed with Alzheimer's and healthy adults with no apparent ...
A new study moves beyond the traditional view of obesity as a general health risk and investigates how obesity-related changes in body fat can send harmful signals to the brain, disrupting brain ...
Hosted on MSN
New blood biomarker predicts progression of Alzheimer's disease even in its earliest stages
A team of researchers at the Sant Pau Research Institute (IR Sant Pau) has demonstrated that the plasma biomarker p-tau217, obtained through a simple blood test, can predict the clinical progression ...
From financial woes to a declining sense of smell, issues that seem unrelated to memory can signal a dementia diagnosis in ...
Alzheimer’s disease affects millions of people worldwide, robbing individuals of their memory, cognitive abilities and independence. While researchers continue searching for medical breakthroughs, one ...
New research has highlighted how lifestyle can potentially delay the onset of Alzheimer’s disease. The most common form of dementia, Alzheimer’s impacts nearly 7 million Americans - and that number is ...
The final stages of Alzheimer’s disease represent one of the most challenging periods for families watching their loved ones navigate this devastating condition. Understanding the critical signs that ...
Novo Nordisk has announced the cessation of the Evoke trials, looking at whether GLP-1 drugs could help tackle Alzheimer’s. Image credit: NurPhoto/Getty ImagesThis article originally appeared on ...
Cochrane review says amyloid-targeting Alzheimer's drugs are ineffective, but the Alzheimer's Association and drug makers ...
Reviewed by Anton Porsteinsson, MD, Director of the University of Rochester Alzheimer’s Disease Care, Research and Education Program (AD-CARE) in New York; and the first William B. and Sheila Konar, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results